New antibody therapy may transform HIV treatment

New York, May 7 : Researchers have developed a new antibody-based drug that has the potential to slow down the replication of the human immunodeficiency virus (HIV) in the body and may also provide a better strategy for long-term control of the deadly infection.

Anti-retroviral therapy — a combination of drugs that slows the replication of HIV in the body — currently used to treat HIV has drawbacks. If a person discontinues his or her treatment, even missing a few doses, the level of the virus in the body is able to rebound quickly.

In the antibody therapy, the researchers used 3BNC117 — a molecule — also called as a broadly neutralising antibody because it has the ability to fight a wide range of HIV strains.

It usually takes several years for the body to begin to make good antibodies against HIV. So there might be an even better effect later on, especially if patients are given more than one dose of 3BNC117, the researchers added.

To determine further benefits of treatment with 3BNC117, the researchers conducted another study, also published in the journal Science, in a mouse model.

The results revealed that 3BNC117 was able to engage the animals’ immune cells and accelerate their clearance of HIV-infected cells.

“This shows that the antibody not only can exert pressure on the virus, but also can shorten the survival of infected cells,” first author of the study Ching-Lan Lu, doctoral student at The Rockefeller University, noted.

Further, the researchers plan to test 3BNC117 in combination with other antibodies that target HIV, to determine whether an even stronger antiviral effect can be found.

Download the U4UVoice App Now:

Leave a Reply

Your email address will not be published. Required fields are marked *